
A)
Vimentin/b-actin
VEGF-B AB - +
Vimentin
β-actin
72
55
55
35
B)
GS/b-actin
VEGF-B AB - +
GS
β-actin
55
35
55
35
C)
AQP4/b-actin
VEGF-B AB - +
AQP4
β-actin
55
35
55
35
D)
Kir4.1/b-actin
VEGF-B AB - +
Kir4.1
β-actin
55
35
55
35
E)
GFAP/b-actin
VEGF-B AB - +
GFAP
β-actin
72
55
35
55
35
F)
AQP4/b-actin
VEGF-B AB - +
GS
β-actin
55
35
55
35
G)
AQP4/b-actin
VEGF-B AB - +
AQP4
β-actin
55
35
55
35
H)
Kir4.1/b-actin
VEGF-B AB - +
Kir4.1
β-actin
55
35
55
35
i)
cell viability
(% of control)
VEGF AB - B NRP1 R1 R1+ NRP1

Supplementary Figure S2. Effect of VEGF-B neutralization on QMMuC-1 Müller cell homeostasis. QMMuC-1 cells were treated with anti-VEGF-B neutralizing antibody (500 ng/mL) for 24 h (**A-D**) or 72 h (**E-H**) and the expression of the main proteins involved in Müller functionality was examined by Western Blot. Effect of VEGF-B neutralization for 24 h on the protein expression of vimentin (**A**), GS (**B**), AQP4 (**C**) and Kir4.1 (**D**) and 72 h on GFAP (**F)**, GS (**F**), AQP4 (**G**) and Kir4.1 (**H**) expression. Data normalized to control values, n=4 per group. **I**, QMMuC-1 Müller cells viability after 72 h neutralization of VEGF-B or its receptors alone (anti-VEGFR1 antibody, 10 μg/mL) or in combination (anti-NRP1 30 μg/mL + anti-VEGFR1 10 μg/mL) measured with Alamar Blue. n=6-9 per group. VEGF AB, VEGF-related antibodies; B, VEGF-B; R1, VEGFR1.